Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 15 de 15
Filter
Add more filters










Publication year range
1.
Bioorg Med Chem Lett ; 20(22): 6680-4, 2010 Nov 15.
Article in English | MEDLINE | ID: mdl-20875742

ABSTRACT

Alphaxalone, a neuroactive steroid containing a 17ß-acetyl group, has potent anesthetic activity in humans. This pharmacological activity is attributed to this steroid's enhancement of γ-amino butyric acid-mediated chloride currents at γ-amino butyric acid type A receptors. The conversion of alphaxalone into Δ(16)-alphaxalone produces an analogue that lacks anesthetic activity in humans and that has greatly diminished receptor actions. By contrast, the corresponding 17ß-carbonitrile analogue of alphaxalone and the Δ(16)-17-carbonitrile analogue both have potent anesthetic and receptor actions. The differential effect of the Δ(16)-double bond on the actions of alphaxalone and the 17ß-carbonitrile analogue is accounted for by a differential effect on the orientation of the 17-acetyl and 17-carbonitrile substituents.


Subject(s)
Anesthetics/pharmacology , Nitriles/chemistry , Pregnanediones/pharmacology , gamma-Aminobutyric Acid/drug effects , Animals , Crystallography, X-Ray , Magnetic Resonance Spectroscopy , Models, Molecular , Pregnanediones/chemistry , Rats , Spectrophotometry, Infrared
2.
Br J Pharmacol ; 158(5): 1322-9, 2009 Nov.
Article in English | MEDLINE | ID: mdl-19702782

ABSTRACT

BACKGROUND AND PURPOSE: Potentiating neurosteroids are some of the most efficacious modulators of the mammalian GABA(A) receptor. One of the crucial interactions may be between the C20 ketone group (D-ring substituent at C17) of the neurosteroid, and the N407 and Y410 residues in the M4 domain of the receptor. In this study, we examined the contribution of hydrogen bonding between 17beta-substituents on the steroid D-ring and the GABA(A) receptor to potentiation by neurosteroids. EXPERIMENTAL APPROACH: Whole-cell and single-channel recordings were made from HEK 293 cells transiently expressing wild-type and mutant alpha1beta2gamma2L GABA(A) receptors. KEY RESULTS: A steroid with a 17beta-carbonitrile group (3alpha5alpha18nor17betaCN) was a potent and efficacious potentiator of the GABA(A) receptor. Potentiation was also shown by a cyclosteroid in which C21 and the C18 methyl group of (3alpha,5alpha)-3-hydroxypregnan-20-one are connected within a six-membered ring containing a double bond as a hydrogen bond acceptor (3alpha5alphaCDNC12), a steroid containing a 17beta-ethyl group on the D-ring (3alpha5alpha17betaEt) and a steroid lacking a 17beta-substituent on the D-ring (3alpha5alpha17H). Single-channel kinetic analysis indicates that the kinetic mechanism of action is the same for the neurosteroid 3alpha5alphaP, 3alpha5alpha18nor17betaCN, 3alpha5alphaCDNC12, 3alpha5alpha17betaEt and 3alpha5alpha17H. Interestingly, 3alpha5alpha17betaEt, at up to 3 microM, was incapable of potentiating the alpha1N407A/Y410F double mutant receptor. CONCLUSIONS AND IMPLICATIONS: Hydrogen bonding between the steroid 17beta-substituent and the GABA(A) receptor is not a critical requirement for channel potentiation. The alpha1N407/Y410 residues are important for neurosteroid potentiation for reasons other than hydrogen bonding between steroid and receptor.


Subject(s)
GABA-A Receptor Agonists , Neurotransmitter Agents/metabolism , Receptors, GABA-A/metabolism , Androstanols/chemistry , Androstanols/pharmacology , Animals , Binding Sites , Cell Line , Humans , Hydrogen Bonding , Mutation , Neurotransmitter Agents/chemistry , Nitriles/chemistry , Nitriles/pharmacology , Norandrostanes/chemistry , Norandrostanes/pharmacology , Patch-Clamp Techniques , Rats , Receptors, GABA-A/genetics , Structure-Activity Relationship , gamma-Aminobutyric Acid/pharmacology
3.
Mol Pharmacol ; 76(4): 754-65, 2009 Oct.
Article in English | MEDLINE | ID: mdl-19596835

ABSTRACT

We have shown that fluorescent, 7-nitro-2,1,3-benzoxadiazol-4-yl amino (NBD)-conjugated neurosteroid analogs photopotentiate GABA(A) receptor function. These compounds seem to photosensitize a modification of receptor function, resulting in long-lived increases in responses to exogenous or synaptic GABA. Here we extend this work to examine the effectiveness of different fluorophore positions, conjugations, steroid structures, and fluorophores. Our results are generally in agreement with the idea that steroids with activity at GABA(A) receptors are the most potent photopotentiators. In particular, we find that an unnatural enantiomer of an effective photopotentiating steroid is relatively weak, excluding the idea that membrane solubility alone, which is identical for enantiomer pairs, is solely responsible for potent photopotentiation. Furthermore, there is a significant correlation between baseline GABA(A) receptor activity and photopotentiation. Curiously, both sulfated steroids, which bind a presumed external neurosteroid antagonist site, and hydroxysteroids, which bind an independent site, are effective. We also find that a rhodamine dye conjugated to a 5beta-reduced 3alpha-hydroxy steroid is a particularly potent and effective photopotentiator, with minimal baseline receptor activity up to 10 muM. Steroid conjugated fluorescein and Alexa Fluor 546 also supported photopotentiation, although the Alexa Fluor conjugate was weaker and required 10-fold higher concentration to achieve similar potentiation to the best NBD and rhodamine conjugates. Filling cells with steroid-conjugated or free fluorophores via whole-cell patch pipette did not support photopotentiation. FM1-43, another membrane-targeted, structurally unrelated fluorophore, also produced photopotentiation at micromolar concentrations. We conclude that further optimization of fluorophore and carrier could produce an effective, selective, light-sensitive GABA(A) receptor modulator.


Subject(s)
Fluorescent Dyes/chemistry , Receptors, GABA-A/chemistry , Animals , Female , Patch-Clamp Techniques , Rats , Xenopus laevis
4.
J Neurophysiol ; 102(2): 1254-64, 2009 Aug.
Article in English | MEDLINE | ID: mdl-19553485

ABSTRACT

Anesthetic steroids with actions at gamma-aminobutyric acid type A receptors (GABA(A)Rs) may access transmembrane domain binding site(s) directly from the plasma cell membrane. Accordingly, the effective concentration in lipid phase and the ability of the steroid to meet pharmacophore requirements for activity will both contribute to observed steady-state potency. Furthermore, onset and offset of receptor effects may be rate limited by lipid partitioning. Here we show that several GABA-active steroids, including naturally occurring neurosteroids, of different lipophilicity differ in kinetics and potency at GABA(A)Rs. The hydrophobicity ranking predicted relative potency of GABA(A)R potentiation and predicted current offset kinetics. Kinetic offset differences among steroids were largely eliminated by gamma-cyclodextrin, a scavenger of unbound steroid, suggesting that affinity differences among the analogues are dwarfed by the contributions of nonspecific accumulation. A 7-nitrobenz-2-oxa-1,3-diazole (NBD)-tagged fluorescent analogue of the low-lipophilicity alphaxalone (C17-NBD-alphaxalone) exhibited faster nonspecific accumulation and departitioning than those of a fluorescent analogue of the high-lipophilicity (3alpha,5alpha)-3-hydroxypregnan-20-one (C17-NBD-3alpha5alphaA). These differences were paralleled by differences in potentiation of GABA(A)R function. The enantiomer of C17-NBD-3alpha5alphaA, which does not satisfy pharmacophore requirements for steroid potentiation, exhibited identical fluorescence kinetics and distribution to C17-NBD-3alpha5alphaA, but was inactive at GABA(A)Rs. Simple simulations supported our major findings, which suggest that neurosteroid binding affinity is low. Therefore both specific (e.g., fulfilling pharmacophore requirements) and nonspecific (e.g., lipid solubility) properties contribute to the potency and longevity of anesthetic steroid action.


Subject(s)
Cell Membrane/drug effects , Neurons/drug effects , Receptors, GABA-A/metabolism , Steroids/pharmacology , Animals , Cell Membrane/physiology , Cells, Cultured , Computer Simulation , Fluorescence , Hippocampus/drug effects , Hippocampus/physiology , Hydrophobic and Hydrophilic Interactions , Kinetics , Membrane Potentials/drug effects , Membrane Potentials/physiology , Models, Neurological , Neurons/physiology , Oxadiazoles , Pregnanolone/analogs & derivatives , Pregnanolone/chemistry , Rats , Steroids/chemistry , Xenopus laevis , gamma-Aminobutyric Acid/metabolism , gamma-Cyclodextrins/chemistry , gamma-Cyclodextrins/pharmacology
5.
Clin Cancer Res ; 14(3): 883-91, 2008 Feb 01.
Article in English | MEDLINE | ID: mdl-18245552

ABSTRACT

PURPOSE: The purpose of the present study was to evaluate the anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb), cetuximab, (IMC-C225) and the anti-EGFRvIII mAb, L8A4, used in combination as delivery agents for boron neutron capture therapy (BNCT) of a rat glioma composed of a mixture of cells expressing either wild-type (F98(EGFR)) or mutant receptors(F98(npEGFRvIII)). EXPERIMENTAL DESIGN: A heavily boronated polyamidoamine dendrimer (BD) was linked by heterobifunctional reagents to produce the boronated mAbs, BD-C225 and BD-L8A4. For in vivo biodistribution and therapy studies, a mixture of tumor cells were implanted intracerebrally into Fischer rats. Biodistribution studies were carried out by administering (125)I-labeled bioconjugates via convection-enhanced delivery (CED), and for therapy studies, nonradiolabeled bioconjugates were used for BNCT. This was carried out 14 days after tumor implantation and 24 h after CED at the Massachusetts Institute of Technology nuclear reactor. RESULTS: Following CED of a mixture of (125)I-BD-C225 and (125)I-BD-L8A4 to rats bearing composite tumors, 61.4% of the injected dose per gram (ID/g) was localized in the tumor compared with 30.8% ID/g for (125)I-BD-L8A4 and 34.7% ID/g for (125)I-BD-C225 alone. The corresponding calculated tumor boron values were 24.4 mug/g for rats that received both mAbs, and 12.3 and 13.8 mug/g, respectively, for BD-L8A4 or BD-C225 alone. The mean survival time of animals bearing composite tumors, which received both mAbs, was 55 days (P < 0.0001) compared with 36 days for BD-L8A4 and 38 days for BD-C225 alone, which were not significantly different from irradiated controls. CONCLUSIONS: Both EGFRvIII and wild-type EGFR tumor cell populations must be targeted using a combination of BD-cetuximab and BD-L8A4. Although in vitro C225 recognized both receptors, in vivo it was incapable of delivering the requisite amount of (10)B for BNCT of EGFRvIII-expressing gliomas.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Boron/analysis , Brain Neoplasms/radiotherapy , ErbB Receptors/analysis , Glioma/radiotherapy , Animals , Binding Sites, Antibody , Boron/immunology , Disease Models, Animal
6.
Clin Cancer Res ; 13(4): 1260-8, 2007 Feb 15.
Article in English | MEDLINE | ID: mdl-17317838

ABSTRACT

PURPOSE: The purpose of the present study was to evaluate the anti-epidermal growth factor monoclonal antibody (mAb) cetuximab (IMC-C225) as a delivery agent for boron neutron capture therapy (BNCT) of a human epidermal growth factor receptor (EGFR) gene-transfected rat glioma, designated as F98(EGFR). EXPERIMENTAL DESIGN: A heavily boronated polyamidoamine dendrimer was chemically linked to cetuximab by means of the heterobifunctional reagents N-succinimidyl 3-(2-pyridyldithio)-propionate and N-(k-maleimido undecanoic acid)-hydrazide. The bioconjugate, designated as BD-C225, was specifically taken up by F98(EGFR) glioma cells in vitro compared with receptor-negative F98 wild-type cells (41.8 versus 9.1 microg/g). For in vivo biodistribution studies, F98(EGFR) cells were implanted stereotactically into the brains of Fischer rats, and 14 days later, BD-C225 was given intracerebrally by either convection enhanced delivery (CED) or direct intratumoral (i.t.) injection. RESULTS: The amount of boron retained by F98(EGFR) gliomas 24 h following CED or i.t. injection was 77.2 and 50.8 microg/g, respectively, with normal brain and blood boron values <0.05 mug/g. Boron neutron capture therapy was carried out at the Massachusetts Institute of Technology Research Reactor 24 h after CED of BD-C225, either alone or in combination with i.v. boronophenylalanine (BPA). The corresponding mean survival times (MST) were 54.5 and 70.9 days (P = 0.017), respectively, with one long-term survivor (more than 180 days). In contrast, the MSTs of irradiated and untreated controls, respectively, were 30.3 and 26.3 days. In a second study, the combination of BD-C225 and BPA plus sodium borocaptate, given by either i.v. or intracarotid injection, was evaluated and the MSTs were equivalent to that obtained with BD-C225 plus i.v. BPA. CONCLUSIONS: The survival data obtained with BD-C225 are comparable with those recently reported by us using boronated mAb L8A4 as the delivery agent. This mAb recognizes the mutant receptor, EGFRvIII. Taken together, these data convincingly show the therapeutic efficacy of molecular targeting of EGFR using a boronated mAb either alone or in combination with BPA and provide a platform for the future development of combinations of high and low molecular weight delivery agents for BNCT of brain tumors.


Subject(s)
Antibodies, Monoclonal/pharmacology , Boron Compounds/administration & dosage , Boron Neutron Capture Therapy/methods , ErbB Receptors/biosynthesis , Glioma/drug therapy , Glioma/radiotherapy , Animals , Antibodies, Monoclonal/chemistry , Antibodies, Monoclonal/immunology , Antibodies, Monoclonal/pharmacokinetics , Antibodies, Monoclonal, Humanized , Boron Compounds/chemistry , Boron Compounds/pharmacokinetics , Cetuximab , Combined Modality Therapy , Dendrimers/administration & dosage , Dendrimers/chemistry , Dendrimers/pharmacokinetics , ErbB Receptors/immunology , ErbB Receptors/metabolism , Glioma/metabolism , Humans , Immunoconjugates/pharmacokinetics , Immunoconjugates/pharmacology , Magnetic Resonance Imaging/methods , Rats , Rats, Inbred F344 , Tissue Distribution
7.
Bioconjug Chem ; 17(5): 1141-50, 2006.
Article in English | MEDLINE | ID: mdl-16984121

ABSTRACT

Liposomes have been a main focus of tumor-selective boron delivery strategies in boron neutron capture therapy (BNCT), a binary method for the treatment of cancer that is based on the nuclear reaction between boron atoms and low-energy thermal neutrons. Three novel carboranyl cholesterol derivatives were prepared as lipid bilayer components for the construction of nontargeted and receptor-targeted boronated liposomes for BNCT. A major structural feature of these novel boronated cholesterol mimics is the replacement of the B and the C ring of cholesterol with a carborane cluster. Computational analyses indicated that all three boronated compounds have structural features and physicochemical properties that are very similar to those of cholesterol. One of the synthesized boronated cholesterol mimics was stably incorporated into non-, folate receptor (FR)-, and vascular endothelial growth factor receptor-2 (VEGFR-2)-targeted liposomes. No major differences were found in appearance, size distribution, and lamellarity between conventional dipalmitoylphosphatidylcholine (DPPC)/cholesterol liposomes, nontargeted, and FR-targeted liposomal formulations of this carboranyl cholesterol derivative. FR-targeted boronated liposomes were taken up extensively in FR overexpressing KB cells in vitro, and the uptake was effectively blocked in the presence of free folate. In contrast, a boronated cholesterol mimic incorporated into nontargeted liposomes showed significantly lower cellular uptake. There was no apparent in vitro cytotoxicity in FR overexpressing KB cells and VEGFR-2 overexpressing 293/KDR cells when these were incubated with boronated FR- and (VEGFR-2)-targeted liposomes, respectively, although the former accumulated extensively in KB cells and the latter effectively interacted with VEGFR-2 by causing autophosphorylation and protecting 293/KDR cells from SLT (Shiga-like toxin)-VEGF cytotoxicity.


Subject(s)
Boron Compounds/metabolism , Boron Neutron Capture Therapy/methods , Cholesterol , Liposomes/metabolism , Boron Compounds/chemistry , Cell Line , Cholesterol/chemistry , Cholesterol/metabolism , Humans , Liposomes/chemistry , Models, Molecular , Molecular Structure , Neoplasms/therapy , Particle Size , Vascular Endothelial Growth Factor A/genetics , Vascular Endothelial Growth Factor A/metabolism , Vascular Endothelial Growth Factor Receptor-2/genetics , Vascular Endothelial Growth Factor Receptor-2/metabolism
8.
Bioorg Med Chem ; 14(20): 6924-32, 2006 Oct 15.
Article in English | MEDLINE | ID: mdl-16828556

ABSTRACT

Three-dimensional quantitative structure-activity relationship (3D-QSAR) using CoMFA and CoMSIA techniques was applied to evaluate 56 pyrimidine nucleosides as substrates of human thymidine kinase 1 (hTK1), 27 of them containing a carborane substituent either at the 3-, 5-, or 3'-position of the 2'-deoxyuridine scaffold. This is the first report describing 3D-QSAR studies of compounds containing boron atoms. Both CoMFA and CoMSIA models were derived from a training set of 47 molecules and the predictive capacity of the CoMSIA model was successfully validated by accurately calculating known phosphorylation rates of both boronated and non-boron hTK1 substrates that were not included in the training set. The optimal CoMSIA model provided the following values: q(2) 0.622, r(2) 0.983, s 0.165, and F 187.5. Contour maps obtained from the CoMSIA model were in agreement with the experimentally determined biological data.


Subject(s)
Boron/chemistry , Quantitative Structure-Activity Relationship , Thymidine Kinase/chemistry , Humans , Models, Molecular , Molecular Structure , Static Electricity , Substrate Specificity
9.
Bioorg Med Chem ; 14(20): 6886-99, 2006 Oct 15.
Article in English | MEDLINE | ID: mdl-16831554

ABSTRACT

Five novel 3-carboranyl thymidine analogues (3CTAs) were designed and synthesized for boron neutron capture therapy (BNCT) of cancer. Phosphorylation of all five 3CTAs was catalyzed by recombinant human thymidine kinase (hTK1) using adenosine triphosphate (ATP) as the phosphate donor. The obtained phosphorylation rates ranged from 4% to 64.5% relative to that of thymidine. The compound with the most favorable hTK1 binding properties had a k(cat)/K(M) value of 57.4% relative to that of thymidine and an IC(50) of inhibition of thymidine phosphorylation by hTK1 of 92 microM. Among the five synthesized 3CTAs, this agent had also the overall most favorable physicochemical properties. Therefore, it may have the potential to replace N5-2OH, the current lead 3CTA, in preclinical studies. An in silico model for the binding of this compound to hTK1 was developed.


Subject(s)
Thymidine/analogs & derivatives , Thymidine/therapeutic use , Binding Sites , Boron Neutron Capture Therapy , Catalysis , Drug Design , Humans , Hydrophobic and Hydrophilic Interactions , Models, Molecular , Molecular Conformation , Neoplasms/radiotherapy , Phosphorylation , Protein Conformation , Protein Structure, Tertiary , Recombinant Proteins/antagonists & inhibitors , Recombinant Proteins/chemistry , Stereoisomerism , Structure-Activity Relationship , Thymidine/chemistry , Thymidine Kinase/antagonists & inhibitors , Thymidine Kinase/chemistry
10.
Clin Cancer Res ; 12(12): 3792-802, 2006 Jun 15.
Article in English | MEDLINE | ID: mdl-16778107

ABSTRACT

PURPOSE: The purpose of the present study was to evaluate a boronated EGFRvIII-specific monoclonal antibody, L8A4, for boron neutron capture therapy (BNCT) of the receptor-positive rat glioma, F98(npEGFRvIII). EXPERIMENTAL DESIGN: A heavily boronated polyamido amine (PAMAM) dendrimer (BD) was chemically linked to L8A4 by two heterobifunctional reagents, N-succinimidyl 3-(2-pyridyldithio)propionate and N-(k-maleimidoundecanoic acid)hydrazide. For in vivo studies, F98 wild-type receptor-negative or EGFRvIII human gene-transfected receptor-positive F98(npEGFRvIII) glioma cells were implanted i.c. into the brains of Fischer rats. Biodistribution studies were initiated 14 days later. Animals received [(125)I]BD-L8A4 by either convection enhanced delivery (CED) or direct i.t. injection and were euthanized 6, 12, 24, or 48 hours later. RESULTS: At 6 hours, equivalent amounts of the bioconjugate were detected in receptor-positive and receptor-negative tumors, but by 24 hours the amounts retained by receptor-positive gliomas were 60.1% following CED and 43.7% following i.t. injection compared with 14.6% ID/g by receptor-negative tumors. Boron concentrations in normal brain, blood, liver, kidneys, and spleen all were at nondetectable levels (<0.5 microg/g) at the corresponding times. Based on these favorable biodistribution data, BNCT studies were initiated at the Massachusetts Institute of Technology Research Reactor-II. Rats received BD-L8A4 ( approximately 40 microg (10)B/ approximately 750 mug protein) by CED either alone or in combination with i.v. boronophenylalanine (BPA; 500 mg/kg). BNCT was carried out 24 hours after administration of the bioconjugate and 2.5 hours after i.v. injection of BPA for those animals that received both agents. Rats that received BD-L8A4 by CED in combination with i.v. BPA had a mean +/- SE survival time of 85.5 +/- 15.5 days with 20% long-term survivors (>6 months) and those that received BD-L8A4 alone had a mean +/- SE survival time of 70.4 +/- 11.1 days with 10% long-term survivors compared with 40.1 +/- 2.2 days for i.v. BPA and 30.3 +/- 1.6 and 26.3 +/- 1.1 days for irradiated and untreated controls, respectively. CONCLUSIONS: These data convincingly show the therapeutic efficacy of molecular targeting of EGFRvIII using either boronated monoclonal antibody L8A4 alone or in combination with BPA and should provide a platform for the future development of combinations of high and low molecular weight delivery agents for BNCT of brain tumors.


Subject(s)
ErbB Receptors/analysis , Glioma/radiotherapy , Animals , Antibodies, Monoclonal/therapeutic use , Boron Compounds/therapeutic use , Boron Neutron Capture Therapy , Brain Neoplasms/pathology , Brain Neoplasms/radiotherapy , ErbB Receptors/genetics , ErbB Receptors/metabolism , Glioma/pathology , Humans , Injections , Iodine Radioisotopes/pharmacokinetics , Iodine Radioisotopes/therapeutic use , Rats , Recombinant Proteins/metabolism , Transfection
11.
Anticancer Agents Med Chem ; 6(2): 127-44, 2006 Mar.
Article in English | MEDLINE | ID: mdl-16529536

ABSTRACT

One category of boron neutron capture therapy (BNCT) agents that has received extensive attention during recent years is 3-carboranyl thymidine analogues (3CTAs). These molecules are phosphorylated to the corresponding 5'-monophosphates by human thymidine kinase 1 (TK1), an enzyme that is up-regulated in dividing malignant cells. Thus, these phosphorylated molecules are selectively entrapped in tumor cells due to the acquired negative charge. This review will analyze design strategies applied for the synthesis of boron-containing nucleosides in general and in particular reference to 3CTAs. Results of biological studies with these molecules will be discussed.


Subject(s)
Boranes/chemical synthesis , Boron Neutron Capture Therapy/methods , Nucleosides/chemical synthesis , Thymidine/analogs & derivatives , Animals , Antineoplastic Agents/chemical synthesis , Antineoplastic Agents/therapeutic use , Boranes/therapeutic use , Humans , Nucleosides/therapeutic use , Nucleotides/chemical synthesis , Nucleotides/therapeutic use , Pyrimidine Nucleosides/chemical synthesis , Pyrimidine Nucleosides/therapeutic use , Thymidine/chemical synthesis , Thymidine Kinase/metabolism
12.
Mol Cancer Ther ; 4(9): 1423-9, 2005 Sep.
Article in English | MEDLINE | ID: mdl-16170035

ABSTRACT

Tumor neovasculature is a potential but, until very recently, unexplored target for boron neutron capture therapy (BNCT) of cancer. In the present report, we describe the construction of a vascular endothelial growth factor (VEGF)-containing bioconjugate that potentially could be used to target up-regulated VEGF receptors (VEGFR), which are overexpressed on tumor neovasculature. A fifth-generation polyamidoamine dendrimer containing 128 reactive amino groups was reacted with 105 to 110 decaborate molecules to produce a macromolecule with 1,050 to 1,100 boron atoms per dendrimer. This was conjugated to thiol groups of VEGF at a 4:1 molar ratio using the heterobifunctional reagent sulfo-LC-SPDP. In addition, the boronated dendrimer was tagged with a near-IR Cy5 dye to allow for near-IR fluorescent imaging of the bioconjugate in vitro and in vivo. As would be predicted, the resulting VEGF-BD/Cy5 bioconjugate was not cytotoxic to HEK293 cells engineered to express 2.5 x 10(6) VEGFR-2 per cell. Furthermore, it showed binding and activation of VEGFR-2 comparable with that of native VEGF. Internalization of VEGF-BD/Cy5 by PAE cells expressing 2.5 x 10(5) VEGFR-2 per cell was inhibited by excess VEGF, indicating a VEGFR-2-mediated mechanism of uptake. Near-IR fluorescent imaging of 4T1 mouse breast carcinoma revealed selective accumulation of VEGF-BD/Cy5, but not BD/Cy5, particularly at the tumor periphery where angiogenesis was most active. Accumulation of VEGF-BD/Cy5 in 4T1 breast carcinoma was diminished in mice pretreated with a toxin-VEGF fusion protein that selectively killed VEGFR-2-overexpressing endothelial cells. Our data lay the groundwork for future studies using the VEGF-BD/Cy5 bioconjugate as a targeting agent for BNCT of tumor neovasculature.


Subject(s)
Boron Compounds/pharmacokinetics , Endothelium, Vascular/drug effects , Mammary Neoplasms, Experimental/blood supply , Neovascularization, Pathologic/drug therapy , Polyamines/pharmacokinetics , Vascular Endothelial Growth Factor A/pharmacology , Animals , Boron Compounds/chemistry , Boron Neutron Capture Therapy , Cell Proliferation/drug effects , Female , Humans , Mammary Neoplasms, Experimental/metabolism , Mice , Mice, Inbred BALB C , Neovascularization, Pathologic/metabolism , Polyamines/chemistry , Receptors, Vascular Endothelial Growth Factor/metabolism , Recombinant Fusion Proteins/administration & dosage , Recombinant Fusion Proteins/pharmacology , Tumor Cells, Cultured , Vascular Endothelial Growth Factor A/administration & dosage
13.
Bioorg Med Chem ; 13(5): 1681-9, 2005 Mar 01.
Article in English | MEDLINE | ID: mdl-15698786

ABSTRACT

Thymidine kinase 1 (TK1) is a key target for antiviral and anticancer chemotherapy. Three-dimensional quantitative structure-activity relationship (3D-QSAR) using comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) techniques was applied to analyze the phosphorylation capacity of a series of 31 TK1 substrates. The optimal predictive CoMFA model with 26 molecules provided the following values: cross-validated r(2) (q(2))=0.651, non-cross-validated r(2)=0.980, standard error of estimate (s)=0.207, F=129.3. For the optimal CoMSIA model the following values were found: q(2)=0.619, r(2)=0.994, s=0.104, F=372.2. The CoMSIA model includes steric, electrostatic, and hydrogen bond donor fields. The predictive capacity of both models was successfully validated by calculating known phosphorylation rates of five TK1 substrates that were not included in the training set. Contour maps obtained from CoMFA and CoMSIA models correlated with the experimentally developed SAR.


Subject(s)
Thymidine Kinase/metabolism , Humans , Models, Molecular , Phosphorylation , Quantitative Structure-Activity Relationship , Substrate Specificity
14.
Appl Radiat Isot ; 61(5): 981-5, 2004 Nov.
Article in English | MEDLINE | ID: mdl-15308179

ABSTRACT

The purpose of the present study was to further evaluate a boronated dendrimer (BD)-epidermal growth factor bioconjugate (BD-EGF), administered by means of convection enhanced delivery (CED), as a molecular targeting agent for boron neutron capture therapy (BNCT) of the F98(EGFR) glioma. Twenty-four hours following CED of (125)I-labeled BD-EGF 47.4% of the injected dose (ID) was retained in F98(EGFR) gliomas compared to 12.3% in F98(WT) (wildtype) receptor negative tumors. Normal brain values were in the range of 5.9-10.1% ID in the tumor bearing cerebral hemisphere. Boron concentrations in F98(EGFR) gliomas were 22.3 and 11.7 microg/g following CED and i.t. injection, respectively. Based on these results, BNCT studies were initiated at the Massachusetts Institute of Technology nuclear reactor (MITRII). The mean survival time (MST) of rats that received BD-EGF either alone or in combination with boronophenylalanine (BPA), injected i.v., were 53+/-13 d and >61+/-14 d, respectively, compared to 40+/-5 d for BPA alone and 31+/-4 d for irradiated controls. These data show that CED improved the radiobiological effectiveness of BD-EGF and lay the groundwork for future studies using combinations of boron delivery agents for NCT of EGFR(+) gliomas.


Subject(s)
Boron Compounds/administration & dosage , Boron Neutron Capture Therapy/methods , Brain Neoplasms/metabolism , Brain Neoplasms/radiotherapy , Epidermal Growth Factor/administration & dosage , ErbB Receptors/metabolism , Glioma/metabolism , Glioma/radiotherapy , Phenylalanine/analogs & derivatives , Animals , Boron Compounds/pharmacokinetics , Brain Neoplasms/genetics , Cell Line, Tumor , Epidermal Growth Factor/pharmacokinetics , ErbB Receptors/genetics , Glioma/genetics , Humans , Injections, Intravenous , Phenylalanine/administration & dosage , Phenylalanine/pharmacokinetics , Radiotherapy Dosage , Rats , Rats, Inbred F344 , Recombinant Proteins/administration & dosage , Recombinant Proteins/pharmacokinetics , Tissue Distribution , Transfection
15.
J Med Chem ; 46(20): 4244-58, 2003 Sep 25.
Article in English | MEDLINE | ID: mdl-13678403

ABSTRACT

Artemisinin (1) and its analogues have been well studied for their antimalarial activity. Here we present the antimalarial activity of some novel C-9-modified artemisinin analogues synthesized using artemisitene as the key intermediate. Further, antileishmanial activity of more than 70 artemisinin derivatives against Leishmania donovani promastigotes is described for the first time. A comprehensive structure-activity relationship study using CoMFA is discussed. These analogues exhibited leishmanicidal activity in micromolar concentrations, and the overall activity profile appears to be similar to that against malaria. Substitution at the C-9beta position was shown to improve the activity in both cases. The 10-deoxo derivatives showed better activity compared to the corresponding lactones. In general, compounds with C-9alpha substitution exhibited lower antimalarial as well as antileishmanial activities compared to the corresponding C-9beta analogues. The importance of the peroxide group for the observed activity of these analogues against leishmania was evident from the fact that 1-deoxyartemisinin analogues did not exhibit antileishmanial activity. The study suggests the possibility of developing artemisinin analogues as potential drug candidates against both malaria and leishmaniasis.


Subject(s)
Antimalarials/chemistry , Antimalarials/pharmacology , Antiprotozoal Agents/chemistry , Antiprotozoal Agents/pharmacology , Artemisinins/chemistry , Artemisinins/pharmacology , Leishmania donovani/drug effects , Sesquiterpenes/chemistry , Sesquiterpenes/pharmacology , Animals , Antimalarials/chemical synthesis , Antiprotozoal Agents/chemical synthesis , Artemisinins/chemical synthesis , Clone Cells , Drug Design , Inhibitory Concentration 50 , L-Lactate Dehydrogenase/analysis , L-Lactate Dehydrogenase/metabolism , Malaria, Falciparum/drug therapy , Models, Molecular , Molecular Conformation , Plasmodium falciparum/drug effects , Plasmodium falciparum/enzymology , Plasmodium falciparum/genetics , Sesquiterpenes/chemical synthesis , Static Electricity , Stereoisomerism , Structure-Activity Relationship
SELECTION OF CITATIONS
SEARCH DETAIL
...